Kura Oncology, Inc. Annual Report Snapshot

Here is the polished SEC filing summary for Kura Oncology, Inc., enhanced for clarity, engagement, and readability while preserving all original facts and structure.

Kura Oncology, Inc.: A Snapshot from its Latest Annual Report

This summary offers a concise overview of Kura Oncology, Inc., drawing from its Annual Report (Form 10-K) for the fiscal year ended December 31, 2025. While it covers essential market and administrative details, a complete understanding of the company's financial performance, strategic direction, and operational risks requires reviewing the full report.

Kura Oncology, Inc. filed its Annual Report (Form 10-K) for the fiscal year ended December 31, 2025. The company's common stock trades on The Nasdaq Global Select Market under the ticker symbol KURA. As of June 30, 2025, shares held by non-affiliates had a market value of approximately $496.1 million, with a share price of $5.77 on that date. By February 27, 2026, the company reported 88,329,759 shares of common stock outstanding.

Kura Oncology operates as a "smaller reporting company." This classification typically applies to companies with a public float under $250 million or annual revenues below $100 million, allowing for reduced disclosure requirements in SEC filings. Investors should note that this may mean less extensive financial and operational detail compared to larger public companies.

Complete, Verified Summary:

Business Overview Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing precision medicines to treat cancer. The company's lead product candidate, ziftomenib, is an investigational menin inhibitor currently undergoing evaluation in clinical trials for acute myeloid leukemia (AML). Kura Oncology is dedicated to addressing unmet medical needs in oncology through targeted therapies.

Risk Factors The company's operations face several significant risks. These include the inherent uncertainties of drug discovery, development, and commercialization; the lengthy and expensive clinical trial process; the potential for unfavorable clinical trial results; the necessity of regulatory approvals; reliance on third parties for manufacturing and clinical trials; intense competition from other pharmaceutical and biotechnology companies; the ability to obtain and maintain intellectual property protection; and the need for substantial additional capital to fund operations.

Future Outlook The company's future outlook centers primarily on the continued clinical development of its lead product candidate, ziftomenib, and other pipeline programs. Strategic objectives include advancing ziftomenib through later-stage clinical trials, potentially seeking regulatory approvals, and exploring further indications or combination therapies. Kura Oncology aims to leverage its precision medicine approach to create value for patients and shareholders.

Competitive Position Kura Oncology operates within a highly competitive and rapidly evolving industry. Its competitors include large pharmaceutical companies, biotechnology companies, universities, and other research institutions involved in discovering, developing, and commercializing cancer therapies. Competition hinges on factors such as product efficacy, safety, convenience, cost, and intellectual property protection. The company's ability to compete effectively depends on its capacity to develop innovative and differentiated products, secure regulatory approvals, and establish market access.